Conference Call and Webcast Today at 1:00 pm ET / 10:00 am PT
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has launched its first commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. Zingo is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous (IV) line placements and blood draws in children three to 18 years of age. Zingo works quickly, within one to three minutes, to relieve pain at the needle insertion site.
"Zingo is the first easy-to-administer, fast-acting local anesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said William T. Zempsky, M.D., Associate Professor, Department of Pediatrics, University of Connecticut; Associate Director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the pediatric trials of Zingo. "Because available topical anesthetic creams can take up to 30 to 60 minutes to work, healthcare providers have had to sacrifice patient comfort when performing the numerous peripheral venous access procedures that occur each day. Zingo will be a source of relief to both them and the children and parents they deal with every day."
"The commercial launch of Zingo is a major milestone that is notable both for our company and for patients. We are fully committed to driving successful market introduction for this exciting new product," said Michael L. Kranda, Anesiva's president and chief executive officer.
Driving Penetration and Uptake for Large Unmet Need
"We are initially focusing
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved